Pardeep Jhund is Professor of Cardiology and Epidemiology in the Institute of Cardiovascular & Medicine Sciences at University of Glasgow, United Kingdom.

Dr Jhund has an interest in clinical trials and the epidemiology of cardiovascular disease, including co-morbidities associated with heart failure. He has experience of using large datasets such as the Scottish Morbidity Record to describe the epidemiology of heart failure, coronary heart disease and stroke.

He has published more than 500 scientific papers and articles, and co-authored a section of Textbook of Vascular Medicine published by Springer in 2019.

Mustafa Arici, MD., is Professor of Medicine (Nephrology) at Hacettepe University in Ankara, Turkey.

His main research interests are concentrated on chronic kidney disease and hypertension with a special focus on mechanisms involved in progression of kidney disease, albuminuria and fibrosis, cardiovascular risks and complications in CKD and dialysis, epidemiology of hypertension and cardiorenal risks of sodium consumption.

Dr. Arici is an “Educational Ambassador” for International Society of Nephrology, a member of “KDIGO Implementation Task Force for Eastern Europe” and “Regional Advisory Group” for International Society of Hypertension. He has also served as a council member for f the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA).
He was elected as a member of the Science Academy in Turkey in 2014.

He is the editor of the book “Management of Chronic Kidney Disease: A Clinician’s Guide” published by Springer in 2014. He authored/co-authored more than 100 articles and book chapters.

Faiez Zannad MD, PhD is Emeritus Professor of Therapeutics at Université de Lorraine, France. As a trialist, he contributed to building the evidence supporting modern HF therapy, notably with beta-blockers, RAASi and MRAs.

He has served as Chairman of the French Society of Hypertension, of the ESC Working Group on Pharmacology and Drug Therapy. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop with meetings in Paris, Washington DC, in Asia and the Middle East.

Professor Zannad published more than 750 peer-reviewed papers. He received the 2014 European Society of Hypertension Paul Milliez Award and the 2017 Lifetime Achievement Award from the ESC-HFA and served as an Eugene Braunwald Scholar in 2019 at Harvard Medical School.

Eberhard Standl is Professor of Medicine, endocrinologist and angiologist at the Munich Diabetes Research Group/ Diabetes Research Institute. He is retired director of the Department of Endocrinology, Diabetology and Metabolism at the Academic Hospital Munich-Schwabing.

His principal areas of research are diabetology, micro- and macrovascular disease, cardioneuropathy, action and degradation of insulin, especially clinical application of human insulin, and epidemiology of cardiovascular diabetic complications.

Professor Standl is vice chair of the EASD study group on cardiovascular complications, and a past-president both of the German Diabetes Union and of IDF Europe. He has received various scientific awards including ,the Harold Rifkin Award of the American Diabetes Association (2005), and the Albert Renold Medal of EASD 2006. He has published some 575 original papers, review articles, textbook chapters and monographs.

Naveed Sattar is a Professor of Metabolic Medicine at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. He is also an Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary, UK.

Dr. Sattar’s main research activity includes investigating the causes, prevention and management of diabetes, obesity and heart disease. He is involved in several lifestyle and drug trials in diabetes and CVD and leads on biomarker initiatives in other trials.

He has authored / co-authored over 800 published papers, and received several national and international prizes for his research, including the Rank Nutrition

Stefan D. Anker has been Professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. He was Professor of Cardiology & Cachexia Research at Charité from 2002 to 2014, and Professor of Innovative Clinical Trials in Göttingen, Germany, from 2014 to 2017.

Rajiv Agarwal, MD is a Professor of Medicine at Indiana University School of Medicine in Indianapolis, Indiana. A graduate of the All India Institute of Medical Sciences, he completed his residency and internship in Nephrology at the University of Texas Southwestern Medical Center at Dallas.

Dr. Agarwal is an internationally recognized leader in the area of hypertension in hemodialysis patients, a continuously funded initiative since 2003 by the National Institutes of Health. He has served on the Board of Directors of Kidney Disease–Improving Global Outcomes (KDIGO).

Dr. Agarwal is Editor for Nephrology Dialysis Transplantation, American Journal of Nephrology, and Journal of the American Society of Hypertension. He has published about 250 original papers and reviews in Nephrology.

At the Ohio State University, Dr. Abraham holds several leadership positions including an Associate Dean position, managing the College of Medicine’s non-cancer clinical and translational research portfolio. As Division Director, Dr. Abraham has developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S.

Mohamed G. Atta, MD, MPH, is Professor of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and Director of Von Hippel Lindau Clinical Care Center at Hopkins. A graduate of Mansoura University School of Medicine in Egypt, he completed his internship and residency training in urology & nephrology at various locations including Johns Hopkins University School of Medicine.

Dr. Atta is a member of the Scientific Council on Kidney of the American Heart Association, the International Society of Nephrology, and the American Society of Nephrology. Dr Atta has participated as principal investigator in several studies and serves as a peer reviewer for the American Journal of Medicine, Kidney International, Clinical Journal of the American Society of Nephrology and a host of other journals.

George L. Bakris is a Professor of Medicine and Dir. of the American Heart Assoc. Comprehensive Hypertension Center at the University of Chicago Medicine. He has published over 800 peer-reviewed articles and book chapters in diabetic kidney disease, hypertension.

Dr. Bakris has served on many national guideline committees, including The Joint National Committee JNC 7 executive committee and writing group, the Am. Diabetes Associ. (ADA) Clinical Practice Guideline Committee, and the K-DOQI, Blood Pressure and Diabetes Guideline committees.

Dr. Bakris is the past-president of the American College of Clinical Pharmacology and the American Society of Hypertension (ASH). He is the recipient of the Irvine Page-Alva Bradley Lifetime Achievement Award-Am Heart Assoc. BP Council (2019).

Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Health and Professor of Medicine at Harvard Medical School. Prior to that he was Chief of Cardiology at VA Boston Healthcare System and served in that role for several years. 

Dr. Bhatt has been listed in Best Doctors in America from 2005 to 2020. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.

Dr. Bhatt’s research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and co-PI of STAMPEDE. He serves as co-chair of the REACH registry and chairs REDUCE-IT, SOLOIST, and SCORED. 

He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease. He is also the Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients.He has authored or co-authored over 1500 publications. His current h-index is 176.

Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi in Jackson, Mississippi, USA. He is also Professor of Physiology.

Professor Antonio Ceriello is Research Consultant at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain and Head of Diabetes Department, Italian Ministry of Health IRCCS Multimedica.

Currently he serves as President of the European Association for the Study of Diabetes (EASD) Study Group on “Diabetes and CardiovascularDiseases” and  Editor in Chief of “Diabetes Research and Clinical Practice”, the official IDF journal.. He is involved as an Expert in the European Society of Cardiology 2020-2022 program for the training of the European cardiologists on the use of the new antidiabetic drugs.

He has chaired the development of major guidelines including the International Diabetes Federation (IDF) Guideline for Management of Postmeal Glucose  in 2008 & update in 2011 and the 2019  ESC/EASD guidelines on diabetes, pre-diabetes, and cardiovascular diseases. 

Professor Ceriello has published widely in the area of diabetes with over 500 original papers and several book chapters. His current h-index is 88.

Andrew Coats is an expert on heart failure. He first described the Muscle Hypothesis of Chronic Heart Failure that explained dyspnoea and exaggerated ventilatory responses in CHF patients. He first described chemoreflex overactivity in CHF and periodic breathing and published the first ever randomised trial of exercise training for CHF.

Alice Y. Y. Cheng, MD, FRCPC,  is a member of the Division of Endocrinology and Metabolism at Credit Valley Hospital in Mississauga and St. Michael’s Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto, Canada.

Dr. Cheng’s research Interests include diabetes, dyslipidemia and thyroid disease. She is also actively involved in guideline development. She served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently Secretary-Treasurer of the Canadian Society of Endocrinology and Metabolism and the Chair of the Guidelines Committee. 

She has received the national Charles H. Best Award and most recently, the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.

Francesco Cosentino is Professor of Cardiology and Chair of Cardiovascular Medicine at the Karolinska Institutet and Karolinska University Hospital in Stockholm, Sweden.

Professor Cosentino is the recipient of grants and prizes from national and international institutions, research councils and private foundations. Prof. Cosentino is past secretary-treasurer of the European Society of Cardiology (ESC) and current chair of the ESC Partnership and Policy Committee. He is chairman of the ESC Guidelines on Diabetes, Pre-diabetes and Cardiovascular Disease and associate editor of European Heart Journal.

He is the leading author of more than 200 original articles published in top-ranking, peer-reviewed journals.

Melanie Davies is Professor of Diabetes Medicine at the University of Leicester, and an Honorary Consultant Diabetologist and Co-Director of the Leicester Diabetes Centre at the University Hospitals of Leicester NHS Trust, Leicester, UK.

Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes mellitus. She is a National Institute for Health Research Senior Investigator Emeritus and Director of the NIHR Leicester Biomedical Research Centre. Professor Davies is the Principal Investigator on a number of large global studies in the field of diabetes, obesity, physical activity, sedentary behavior and cardiovascular disease and has served as an expert for the National Institute for Health and Care Excellence (NICE) on a number of guideline groups. 

Professor Davies was co-chair of EASD/ADA’s recent Consensus Report on T2DM Management. She  has published over 550 original articles in national and international peer-reviewed journals, such as the Lancet, NEJM and the BMJ. She was awarded the CBE (Commander of the Most Excellent Order of the British Empire) in the 2016 New Year’s Honour’s List for services to diabetes research and awarded Fellowship of the Academy of Medical Sciences in 2018.

Wolfram Doehner MD, PhD, FESC is Professor of Interdisciplinary Stroke Research at the Charité – Universitätsmedizin Berlin, Germany. He works at the Center for Stroke Research Berlin (CSB) and the Dept of Cardiology at the Virchow Hospital of the Charité. He is a cardiologist and specialist for internal and nutritional medicine. 

He is a board member of the ESC Council on Stroke. Professor Doehner was Chair (2016-2018) of the study group on heart and brain interaction for the HFA and Secretary for the rehabilitation section for the European Association on Preventive Cardiology (EAPC).

Ralph A. DeFronzo, MD, is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Deputy Director of the Texas Diabetes Institute, San Antonio, Texas. 

His major interests focus on the pathogenesis and treatment of type 2 diabetes mellitus and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome. He has more than 800 articles published in peer-reviewed medical journals.

For his work in this area, Dr. DeFronzo has received many national and international awards including the Banting Award from the ADA (2008), the Claude Bernard Award from the EASD (2008) and most recently, Dr. DeFronzo received the Hamm International Prize (2017). These represent the highest scientific achievement awards given by the American and European Diabetes Associations, respectively.

Gerasimos Filippatos is currently Dean, of the School of Medicine, and Professor of Cardiology, at the University of Cyprus & National and Kapodistrian University of Athens, Greece. He studied Medicine at the University of Patras, Greece, and earned his doctorate cum laude from the University of Athens. He subsequently completed his clinical training in Chicago, USA, and Cambridge, UK.

Paola Fioretto is Professor of Medicine at the University of Padova, Italy. She started her research on renal physiology in diabetes and, during her Fellowship at the University of Minnesota, she devoted her interest to renal structure in diabetes.

Her research interest includes the effects of glucose lowering therapies on the development and progression of diabetic kidney disease. Among her contributions, the description of the heterogeneity in the structural lesions in type 2 diabetes, and of reversal of diabetic glomerulopathy lesions in patients with type 1 diabetes after pancreas transplantation. 

She has received several awards, including the Albert Renold award and Golgi Prize from the EASD (European Association for the Study of Diabetes) and  a Career Development Award from JDFI. She has been Vice President of the EASD (2014-2017), President of the European Diabetic Nephropathy Study Group of the EASD (2005-2007). She has published over 180 peer reviewed papers and 30 book chapters.

Luc Van Gaal, MD, PhD, isProfessor Emeritus of Medicine at Antwerp University and former head of the Department of Endocrinology, Diabetology and Metabolism at the University Hospital.

Professor Van Gaal’s main clinical and research interests are related to obesity, type 2 diabetes and lipid metabolism. He participated in and/or featured as coordinator or principal investigator in a number of clinical trials in the field of obesity and diabetes. He is also involved in a number of EU consortia for metabolic diseases.

Professor Van Gaal has published more than 200 papers in international medical journals, mainly in the areas of general endocrinology, obesity, diabetes and lipids, and has contributed to a number of textbooks about obesity.

Richard J. Glassock, MD, FASN,  is Professor Emeritus at the David Geffen School of Medicine at UCLA and an independent medical consultant. His main interests are in glomerular disease, CKD, and clinical nephrology

He is the Past President of the American Society of Nephrology (ASN) and the National Kidney Foundation (NKF) and Past Chairman of the American Board of Internal Medicine. He was the founding Editor-in-Chief of the ASN NephSAP and Journal of the American Society of Nephrology (2002) and is an Editor of the nephrology section of UpToDate and Associate Editor of the American Journal of Nephrology.

Professor Glassrock has received numerous awards including  He has received the NKF David Hume Memorial Award, the ASN Robert Narins Award and the Medal of Excellence Award from the American Association of Kidney Patients. He is a Master of the American College of Physicians and a Fellow of the Royal College of Physicians (UK).

He has published over 750 original papers, books, book chapters, and reviews. 

Francesco Giorgino is Professor of Endocrinology and Metabolism and Chairman of the Department of Emergency and Organ Transplantation at the University of Bari Aldo Moro, Bari, Italy. He is also Chief of the Division of Endocrinology at the University Hospital Policlinico Consorziale in Bari, Italy. 

Professor Giorgino’s research interests include the mechanisms leading to insulin resistance and beta-cell dysfunction in type 2 diabetes with a particular focus on skeletal muscle metabolism and organ cross-talk, inflammation and lipotoxicity, and the effects of diabetes drugs on pancreatic islets and the cardiovascular system. He has also been involved in several clinical trials investigating the effects of glucose-lowering drugs in individuals with type 2 diabetes.

Professor Giorgino has received distinguished scientific awards from various international and national institutions, including the Juvenile Diabetes Research Foundation International (JDRF) Fellowship (New York, NY, USA), the Mary K. Iacocca Foundation Fellowship (Boston, MA, USA), the Glaxo-Wellcome Award from the European Association for the Study of Diabetes (EASD), the Aldo Pinchera and Cassano Awards from the Italian Society of Endocrinology, 

He has published more than 250 original and review articles in prestigious scientific journals.

Stephan von Haehling, MD, PhD, DIC, FESC is a consultant cardiologist and Associate Professor of Medicine at the Department of Cardiology and Pneumology at the University Medical Center Göttingen, Germany. He obtained his MD at the Institute of Immunology at Charité Medical School, Berlin, Germany. His PhD was awarded by Imperial College, London, UK after he completed studies into inflammatory mechanisms of heart failure at the National Heart and Lung Institute in London. Dr. von Haehling has authored more than 250 original research papers, review articles, and editorials. His research interests include the pathophysiology of heart failure, muscle wasting, sarcopenia, biomarkers, cardio-oncology, and novel treatments.

Hiddo J. Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen. 

Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with diabetes. He is active in clinical trials focused on renal and cardiovascular complications of type 2 diabetes.

He served as a member of the Work Group that developed the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Diseases. He is an editorial board member of the Clinical Journal of the American Society of Nephrology. He has authored and co-authored over 200 peer-reviewed publications.

Dr. James Januzzi is currently the Hutter Family Professor of Medicine at Harvard Medical School. Dr. Januzzi graduated as the top-ranked student in the Class of 1994 from New York Medical College in Valhalla, NY. He joined the staff at the Massachusetts General Hospital in 2000, and is a clinician, teacher, and experienced clinical researcher and clinical trialist.

Kamyar Kalantar-Zadeh, MD, MPH, PhD, is Professor of Medicine, Pediatrics and Public Health and Chief of the Division of Nephrology and Hypertension at UC Irvine. 

Dr. Kalantar-Zadeh research interests include renal nutrition and dietary management, kidney disease outcome and epidemiology, cardiovascular risks in CKD, malnutrition and wasting in chronic diseases, inflammation and cachexia, anemia and iron deficiency.

He  is a member and co-chair of the joint steering committee of the World Kidney Day (WKD), past president of the International Society of Renal Nutrition & Metabolism (ISRNM) and International Federation of Kidney Foundation (IFKF). He is also the founder and director of the Harold Simmons Center for Kidney Disease Research & Epidemiology.

He is an editor-in-chief, associate editor, or a member of the editorial board of many renowned peer-reviewed journals including in American Journal of Nephrology, American Journal of Kidney Diseases, Cardiorenal Medicine, Journal of Cachexia, Sarcopenia and Muscle. He has authored 4 textbooks, more than 900 papers and over 20 chapters.

Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardio Metabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. He received training in internal medicine and cardiovascular disease at Yale New Haven Hospital and Yale University School of Medicine; and training in clinical research, epidemiology, and health policy through the Robert Wood Johnson Clinical Scholars Program at Yale University. Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes. He has authored and co-authored more than 200 peer-reviewed publications, including scientific statements and position documents. He is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

Friedrich Köhler, MD, FESC is Senior Physician in Cardiology at the Medical Department, Division of Cardiology and Angiology and Professor for Cardiovascular Telemedicine at Charité – Universitätsmedizin Berlin. He is also Director of the Centre for Cardiovascular Telemedicine which specializes in research and development projects of remote patient management of heart failure patients.

From 2013-2018 he was Principal Investigator of the publicly funded “Telemedical Interventional Management in Heart Failure II” trial. He is currently working on taskforces for Digital Medicine in the European Society of Cardiology and German Society for Internal Medicine (DGIM).

Marco Metra is Full Professor of Cardiology and Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, and Editor-in-Chief of the European Journal of Heart Failure and Senior Consulting Editor of the European Heart Journal.

Nikolaus Marx, born in 1968, is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany. Professor Marx is a member of several organisations within the field of cardiology and diabetes, including the European Society of Cardiology, American Heart Association (AHA), German Diabetes Association and the European Association for the Study of Diabetes.

Sankar Dass Navaneethan, MD, MS, MPH. is Professor of Medicine and Director of Clinical Research, Section of Nephrology at Baylor College of Medicine in Houston, Texas. 

He is a clinician scientist with major research interests in diabetic kidney disease, obesity, and intentional weight loss in CKD, cardiovascular disease in kidney disease, health services research, and systematic reviews in nephrology. He has authored over 225 peer-reviewed publications and is currently involved in multiple clinical studies. 

He served as a member of the Work Group that developed the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Diseases. He also serves on various committees of the NKF and the American Society of Nephrology.v

Michael Nauckis a Professor of Medicine at Georg-August University, Göttingen, and Ruhr-University, Bochum, and Head of Clinical Research Diabetes at the Diabetes Division of St. Josef-Hospital, Germany. 

He has a particular research interest in the role and impact of gastrointestinal peptide hormones in the physiological and therapeutic stimulation of insulin secretion. He has been acknowledged for major contributions to the development of new therapeutic agents for the treatment of type 2 diabetes based on antidiabetic properties of the gut hormone GLP-1, e.g. incretin-based glucose-lowering medications (GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4). Additional areas of interest are spontaneous hypoglycemia, pancreas transplantation, cardiovascular disease in type 2 diabetic patients and its modulation by different glucose-lowering therapies.

Professor Nauck has been honored with several awards for his research including  the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the Deutsche Diabetes-Gesellschaft (German Diabetes Association). He is a member of a number of professional societies, including the German, European and American Diabetes Associations, the International Diabetes Federation and the American Physiological Society. 

He has served as reviewer for all major diabetes journals and has published more than 190 original articles, 144 reviews and book chapters, and over 400 meeting abstracts.

Mark Petrie is Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and a cardiologist at the Golden Jubilee National Hospital, Glasgow, and Glasgow Royal Infirmary, UK. Professor Petrie’s research interests focus on diabetes and cardiovascular disease, structural intervention in heart failure, subcutaneous furosemide in heart failure, revascularisation in heart failure, peripartum cardiomyopathy, microvascular disease in heart failure with preserved ejection fraction, cardiac remodelling, iron in heart failure and cardio-oncology. He has leadership roles in many trials including STICH, REVIVED, Dapa-HF, EMPACT-MI, STEP-HFpEF, REALIZE-K, IRONMAN, PARADISE-MI and has chaired or been a member of over 40 Clinical Events Committees for major trials (eg EMPA-REG, DELIVER, CAROLINA, TRUE-HF). Mark has published over 220 original publications many in high impact factor journals such as NEJM, Lancet, JAMA, Circulation and JACC. He was an author of the ESC NSTEMI guidelines and a reviewer of the ESC Heart failure guidelines.

Giuseppe M.C. Rosano, MD, PhD, is Professor of Cardiology and Consultant Cardiologist at St. George’s Hospital NHS Trust University of London, United Kingdom where he is also the Director of the MSc in Heart Failure.
G.R. received his medical degree and his specialisation in cardiovascular medicine from “La Sapienza” University of Rome in Rome, Italy, and his PhD in Medical Sciences from the Imperial College of Science and Technology in London, United Kingdom.
G.R. has served as member of the CVWP of the European Medicines Agency since July 2020, he has been board member of the Italian Space Agency and member of the pricing and reimbursement committee at the Italian Drug Agency.
G.R. is fellow of the European Society of Cardiology, the Heart Failure Association, the American College of Cardiology, and the Italian Federation of Cardiology. He serves as Editorial Board Member for European Heart Journal, European Journal of Heart Failure, European Heart Journal—Cardiovascular Pharmacotherapy, ESC Heart Failure, Cardiovascular Diabetology, Nature Research Scientific Reports, Cardiovascular Reviews, Advances in Therapy, European Cardiology Review, and Climacteric.
G.R. has authored or co-authored more than 500 peer-reviewed articles.
He is the president-elect of the Heart Failure Association of the ESC.

Mikael Rydén is a Professor of Cardiology at the Faculty of Medicine, Cairo University..

Patrick Rossignol, MD, PhD, is a nephrologist and vascular medicine specialist, European Society of Hypertension-certified hypertension specialist, and Professor of Therapeutics at the University of Lorraine, France. Since 2018, he has been director of the Nancy University Hospital Inserm Clinical Investigation Centre.

His major interests focus on the mechanisms of transition of hypertension and metabolic disorders to the cardiorenal syndrome in heart failure. He has participated in four EU FP programmes across the heart failure spectrum and has been a EURECA-m (cardiorenal working group of ERA-EDTA) member since its creation in 2009. 

He is a board member in the cardiorenal dysfunction and translation committees of the HFA of the European Society of Cardiology. He is the Kidney Disease Clinical Trialists think-tank course director, gathering academic and industry KOLs, FDA/EMA members.

Peter Rossing MD, DMSc, is the head of complications research at Steno Diabetes Center in Gentofte, and clinical professor in diabetic angiopathy at University of Copenhagen.

Dr. Rossing’s research is focused on complications in diabetes with focus on renal and cardiovascular complications. He identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been an international/national investigator or partner in intervention studies or cohort studies, member of the steering group for PERL, the phase 3 renal outcome studies Fidelio-DKD/Figaro-DKD, DAPA-CKD and FLOW studying treatment of diabetic kidney disease.

Dr. Rossing is Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry. He has co-authored over 390 papers.

Magdalena Madero, MD is the Chief of Nephrology at the Instituto Nacional de Cardiología Ignacio Chávez, Mexico. She completed training in internal medicine at St Elisabeth’s Medical Center Boston, MA, and in nephrology at Tufts Medical Center,Boston, MA.

Dr. Madero’s clinical research interests include CKD progression, complications and outcomes in addition to CKD of unknown origin and chronic renal replacement therapies. She has over 70 publications and 3000 citations. She runs one of the largest renal fellowship programs in the country at the National Heart Institute.

Dr, Madro currently serves as Chair on the International Society of Nephrology (ISN) board for Latin America. She previously served as President of one of the Mexican Societies of Nephrology (IMIN), an International Editor for the American Journal of Kidney Diseases (2016-2021) and a member of the Kidney Disease Improving Global Outcomes Executive Committee (2018-2021).

Dr. Ajay K. Singh is Senior Associate Dean for Postgraduate Medical Education at Harvard Medical School and Director, Master in Medical Sciences in Clinical Investigation (MMSCI) Program. He has been Executive Director for the Dubai Harvard Foundation of Medical Research since 2008.

Dr. Singh’s interests are in clinical research – with a particular focus on the anemia of chronic kidney disease. He has led groundbreaking studies in anemia of kidney disease, including the CHOIR study, and is Principal Investigator for the ASCEND  phase 3 program.

He is the author of over 160 original contributions and review articles, as well as author/editor of 11 books in internal medicine and nephrology. Dr. Singh is a Fellow of the Royal College of Physicians in London, and has an MBA from Boston University.

Kavita Sharma MD, is an Assistant Professor of Medicine in Advanced Heart Failure/Transplant Cardiology in the Division of Cardiology at the Johns Hopkins University School of Medicine. She is the Director of the Johns Hopkins Heart Failure with Preserved Ejection Fraction Program. 

Dr. Sharma’s clinical interests include advanced heart failure diagnosis and management, heart transplantation, and mechanical circulatory support including left ventricular assist devices. She has a specialized interest in heart failure with preserved ejection fraction (HFpEF), and directs one of the largest programs in the country dedicated to caring for patients with this condition. She is the principal investigator of numerous clinical and translational trials in HFpEF and leads a team of nurses, research coordinators, and fellows-in-training in this multifaceted program.

Dr. Sharma is a member of the American Heart Association, the American College of Cardiology, the Heart Failure Society of America, and the International Society of Heart and Lung Transplantation.

Gianluigi Savarese is an Italian cardiologist, currently Associate Professor of Cardiology at the Department of Medicine, Karolinska Institutet, Stockholm, Sweden and Consultant in Heart Failure at the Karolinska University Hospital, Stockholm, Sweden. He received his MD from Federico II University in Naples (Italy) in 2010 and underwent cardiology residency (2011-2016) at the same Institution. In 2013-2014 he was guest fellow at the Center for Molecular Cardiology of the University of Zurich (Switzerland) headed by Prof TF Luscher, where he investigated the molecular mechanisms of heart failure. In 2017 he got the title of heart failure specialist from the University of Zurich, the Heart Failure Association of the European Society of Cardiology and the European Heart Academy. In 2018 he received his PhD from the Karolinska Institutet (Stockholm-Sweden), with a thesis entitled “Biomarkers for eligibility and surrogate endpoints in heart failure trials”. He is currently fellow of the European Society of Cardiology (FESC) and of the Heart Failure Association (FHFA), former secretary and current board member of the ESC working group on cardiovascular pharmacotherapy and board member of the Heart Failure Association of the European Society of Cardiology.

Over the last 5 years, he has published more than 120 articles on top peer reviewed journals. Major focus in his research is heart failure, with a particular interest in phenotyping heart failure with preserved and mid-range ejection fraction, biomarkers and selection criteria for HF clinical trials. He is heavily involved in registry studies (Swedish Heart Failure Registry, HFA registry) and he has several research collaborations in Europe and USA. He has worked as reviewer for several peer-reviewed journals (EHJ, EJHF, JACC, Annals of Internal Medicine, International Journal of Cardiology, Journal of Cardiovascular Medicine, Journal of Cardiac Failure, European Heart Journal – Cardiovascular Pharmacotherapy, etc) and he is currently editor for Plos One, European Heart Journal Open and and European Heart Journal – Case reports. He is expert in meta-analyses, big data analyses and registry-based research

Harriette Van Spall, MD, MPH, is a cardiologist in the Department of Medicine at McMaster University. She is also a scientist in the knowledge translation and heart failure programs at the Population Health Research Institute where she focuses on health systems improvement pertaining to cardiovascular disease. 

Dr. Van Spall is also a scientist in the knowledge translation and heart failure programs at the Population Health Research Institute where she focuses on health systems improvement pertaining to cardiovascular disease. She has won several research awards, and has published her work in high-impact medical journals, including JAMA, Lancet, Circulation and Annals of Internal Medicine. 

She is a member of the College of Reviewers at CIHR and serves as an editorial board member or associate editor at several journals. 

S. Lale Tokgözoğlu, MD, FACC, FESC, is Professor of Cardiology at Hacettepe University, Ankara, Turkey.

Professor Tokgözoğlu is Past-President of the European Atherosclerosis Society. She has served on the Board of the Turkish Society of Cardiology and was elected as its first female President, holding the post from 2014-2016. During that time, she worked with the Ministry of Health to develop heart health policies and strategies. She has contributed to several Guidelines and Consensus Papers on dyslipidemia and Preventive Cardiology both in Europe and nationally and was a member of the Steering Committee of the EUROASPIRE III-V studies which were the landmark studies defining preventive measures in Europe.

She  has been honored with several awards for her research including most recently  the Paul Dudley White International Science Team Award (2017) and The Metrodora Award for Global leader in Health and Science (2020). She has authorized and co-authored more than 400 publications, 3 books and several book chapters.

Christoph Wanner is a Professor of medicine in the Division of Nephrology and Head of the Division of Nephrology at the University Hospital of Würzburg, Germany.

Professor Wanner’s areas of interest are metabolic disorders and cardiovascular outcomes in patients with diabetic kidney and other rare diseases. He is President of ERA – European Renal Association and formerly served as chairman of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry and an executive committee member of KDIGO.

He has published more than 500 scientific papers and articles on subjects including renal dialysis, chronic kidney failure, LDLs, type 2 diabetes and cardiovascular diseases. He serves as editor-in-chief of the Journal of Renal Nutrition and a member of the editorial review boards of many other journals

Dr. Shelley Zieroth, MD FRCPC is professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics. She is also Head of the Medical Heart Failure Program for the Winnipeg Regional Health Authority, Cardiac Sciences Program.

Her area of research examines the efficacy of new treatments including food derived bioactives, in heart failure.  She is involved in several heart failure clinical trials as a PI, is National Lead for EMPULSE, DETERMINE and FINE-ARTS clinical trials and she is on the Steering Committee of PARAGLIDE.   

Dr. Zieroth is Past-President of the Canadian Heart Failure Society and on the Canadian Cardiovascular Society Primary Panels for both the Heart Failure and Heart Transplant Guidelines. She is also President-Elect of the Federation of Medical Women of Canada.